
Harpoon Therapeutics HARP
Quarterly report 2023-Q3
added 05-16-2026
Harpoon Therapeutics General and Administrative Expenses 2011-2026 | HARP
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Harpoon Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 18.8 M | 18.3 M | 16.2 M | 22.4 M | 6.11 M | 3.61 M | 3.37 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 22.4 M | 3.37 M | 12.7 M |
Quarterly General and Administrative Expenses Harpoon Therapeutics
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 4.26 M | 3.8 M | 4.18 M | - | 4.53 M | 5.06 M | 5.4 M | - | 4.19 M | 4.34 M | 4.6 M | 3.92 M | 4.43 M | 3.94 M | 3.91 M | 4.33 M | 8.49 M | 3.73 M | 5.83 M | 2.22 M | 1.94 M | 967 K | 982 K | 912 K | 1.01 M | 847 K | 843 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.49 M | 843 K | 3.55 M |
General and Administrative Expenses of other stocks in the Biotechnology industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
FSD Pharma
HUGE
|
9.05 M | - | 5743.5 % | $ 69.7 M | ||
|
MorphoSys AG
MOR
|
78.3 M | - | 2.43 % | $ 254 M | ||
|
Happiness Biotech Group Limited
HAPP
|
2.31 M | - | 1.35 % | $ 17.8 M | ||
|
AgeX Therapeutics
AGE
|
11 M | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
900 M | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
1.4 B | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
7.15 M | - | -13.47 % | $ 169 M | ||
|
Genfit SA
GNFT
|
16.2 M | - | 2.54 % | $ 160 B | ||
|
AstraZeneca PLC
AZN
|
19.9 B | - | - | $ 96.9 B | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.66 M | - | -1.52 % | $ 24.7 M | ||
|
Athira Pharma
ATHA
|
16.7 M | - | - | $ 269 M | ||
|
BiondVax Pharmaceuticals Ltd.
BVXV
|
24.5 M | - | 0.74 % | $ 768 M | ||
|
Galera Therapeutics
GRTX
|
5.69 M | - | -32.59 % | $ 7.61 M | ||
|
Midatech Pharma plc
MTP
|
4.95 M | - | -18.52 % | $ 27.3 M | ||
|
Esperion Therapeutics
ESPR
|
166 M | $ 3.14 | 0.32 % | $ 653 M | ||
|
Eton Pharmaceuticals
ETON
|
35.8 M | $ 35.15 | 2.03 % | $ 946 M | ||
|
Forte Biosciences
FBRX
|
12.4 M | $ 21.07 | 3.73 % | $ 273 M | ||
|
Институт стволовых клеток человека
ISKJ
|
25.8 M | - | - | - | ||
|
Checkmate Pharmaceuticals
CMPI
|
15.7 M | - | - | $ 231 M | ||
|
Celyad Oncology SA
CYAD
|
10.5 M | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
95.1 M | - | -7.31 % | $ 87 M | ||
|
Grifols, S.A.
GRFS
|
1.26 B | $ 8.09 | -1.28 % | $ 5.5 B | ||
|
Generation Bio Co.
GBIO
|
37.8 M | - | - | $ 344 M | ||
|
IMV
IMV
|
17 M | - | - | $ 13.1 M | ||
|
Akero Therapeutics
AKRO
|
37.9 M | - | - | $ 3.67 B | ||
|
BioNTech SE
BNTX
|
514 M | $ 90.42 | 0.07 % | $ 21.9 B | ||
|
Autolus Therapeutics plc
AUTL
|
132 M | $ 1.65 | 1.81 % | $ 439 M | ||
|
Ayala Pharmaceuticals
AYLA
|
1.53 M | - | - | $ 7.46 M | ||
|
Heron Therapeutics
HRTX
|
54.6 M | $ 0.86 | 1.44 % | $ 143 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
7.72 M | - | -4.36 % | $ 27 M | ||
|
Incyte Corporation
INCY
|
1.38 B | $ 96.77 | -0.32 % | $ 18.9 B | ||
|
Compugen Ltd.
CGEN
|
8.89 M | $ 2.6 | -4.07 % | $ 243 M | ||
|
Ionis Pharmaceuticals
IONS
|
394 M | $ 75.11 | 0.07 % | $ 12 B | ||
|
Anika Therapeutics
ANIK
|
49.1 M | $ 14.99 | -0.99 % | $ 215 M | ||
|
Advaxis
ADXS
|
12.2 M | - | -9.65 % | $ 45.9 M | ||
|
Aeterna Zentaris
AEZS
|
10.1 M | - | 5.93 % | $ 314 M | ||
|
Aeglea BioTherapeutics
AGLE
|
47.9 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
100 M | - | - | $ 867 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
17 M | - | - | $ 26.5 M | ||
|
Can-Fite BioPharma Ltd.
CANF
|
3.66 M | $ 3.29 | -0.98 % | $ 5.42 M | ||
|
AIkido Pharma
AIKI
|
23.8 M | - | 1.93 % | $ 17.4 M | ||
|
Aptose Biosciences
APTO
|
13.4 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
19.8 M | - | -39.0 % | $ 4.57 M | ||
|
Coherus BioSciences
CHRS
|
101 M | $ 1.54 | 1.99 % | $ 180 M | ||
|
Akouos
AKUS
|
22.2 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
69.6 M | - | -0.23 % | $ 916 M | ||
|
AlloVir
ALVR
|
11 M | - | 4.14 % | $ 49.1 M | ||
|
Allakos
ALLK
|
38.8 M | - | - | $ 28.6 M | ||
|
Arcutis Biotherapeutics
ARQT
|
275 M | $ 20.65 | 0.85 % | $ 2.63 B | ||
|
Allena Pharmaceuticals
ALNA
|
12.7 M | - | 3.16 % | $ 1.9 M |